Novartis obtained worldwide rights to ABO2203, Abogen’s clinical-stage mRNA-encoded CD19×CD3 T-cell engager for autoimmune disease, plus options on additional RNA programs. The $575 million upfront payment is unusually large for an early clinical RNA-immunology…
A peer-reviewed pediatric AML study integrates paired diagnosis–relapse single-cell data with larger outcome cohorts to identify rare chemoresistant cell states that improve risk stratification and nominate drug vulnerabilities. The framework is translationally credible, but…
The final GLOW analysis reports durable progression-free and overall-survival advantages for fixed-duration ibrutinib plus venetoclax over chlorambucil plus obinutuzumab in older or comorbid untreated chronic lymphocytic leukemia. The long follow-up strengthens the regimen’s internal…
Osaka University researchers report a modular mRNA–lipid-nanoparticle system that generates transient CAR activity in vivo and uses mRNA methylation state to tune immune programs. Target substitution across FAP, EpCAM, LGR5 and CD133 supports platform…
A peer-reviewed Phase 1b/2 study of zilovertamab plus ibrutinib shows ROR1 occupancy and pathway modulation, but the small randomized cohort did not improve complete response, overall response or progression-free survival versus ibrutinib alone. An…
Foghorn and Lilly will not advance the Phase 1 SMARCA2 inhibitor FHD-909 into expansion and will also stop their selective SMARCA2 degrader program. Foghorn disclosed an approximately 40% workforce reduction and said it will…
A peer-reviewed Leukemia letter reports increased ROR1 expression in mantle-cell lymphoma specimens after CD19 CAR-T relapse and shows that experimental ROR1/CD3 T-cell engagers kill resistant patient-derived cells and control mouse tumors. The work identifies…
Monte Rosa reported randomized Phase 1 GFORCE-1 data in 108 obese adults with elevated cardiovascular risk. Four weeks of oral NEK7-directed molecular glue MRT-8102 produced 80–90% median NEK7 degradation and broad reductions in inflammatory…
An online-first, peer-reviewed Nature Genetics study maps two cis-regulatory brakes on embryonic ζ-globin (HBZ) and uses base editing to reactivate it in mouse and patient-derived erythroid models of severe α-thalassemia. This is a compelling…
TriGemX Bio, formerly Kallyope, announced a $94 million financing to run Phase 3 studies of elismetrep, an oral TRPM8 blocker for acute migraine. The capital is new and the pivotal program is underway, but…
